Mallinckrodt, Endo complete merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 01 2025
0mins
Should l Buy ?
Merger Completion: Mallinckrodt and Endo have successfully merged to form a diversified therapeutics leader, aiming for significant annual pre-tax operating synergies of at least $150M by Year 3.
Future Plans: The new company plans to spin off Par Health and is expected to be listed on the New York Stock Exchange, pending approval from Mallinckrodt's Board of Directors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
